INO
Inovio Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$111.07M
P/E Ratio
—
EPS
$-1.58
Beta
1.44
52W High
$2.98
52W Low
$1.03
50-Day MA
$1.32
200-Day MA
$1.85
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
16.58
PEG Ratio
0.00
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA drugs to treat and protect people from diseases associated with the human papillomavirus (HPV), cancer, and infectious diseases.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-54.21M |
| EBITDA | $-82.36M |
| Operating Margin | 0.00% |
| Return on Equity | -296.40% |
| Return on Assets | -76.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.35 |
| Price-to-Book | 18.10 |
| Price-to-Sales (TTM) | 1712.37 |
| EV/Revenue | 921.12 |
| EV/EBITDA | -1.09 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $82.27M |
| Float | $81.93M |
| % Insiders | 0.39% |
| % Institutions | 47.26% |
Analyst Ratings
Consensus ($5.96 target)
2
Strong Buy2
Buy2
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026